JPH056527B2 - - Google Patents
Info
- Publication number
- JPH056527B2 JPH056527B2 JP59180224A JP18022484A JPH056527B2 JP H056527 B2 JPH056527 B2 JP H056527B2 JP 59180224 A JP59180224 A JP 59180224A JP 18022484 A JP18022484 A JP 18022484A JP H056527 B2 JPH056527 B2 JP H056527B2
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- carbenoxolone
- peptic ulcer
- composition according
- carbopol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims description 44
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims description 29
- 229960002252 carbenoxolone sodium Drugs 0.000 claims description 24
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 18
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 18
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 17
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 230000002467 anti-pepsin effect Effects 0.000 claims description 10
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 229940069428 antacid Drugs 0.000 claims description 3
- 239000003159 antacid agent Substances 0.000 claims description 3
- 230000001458 anti-acid effect Effects 0.000 claims description 3
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 13
- 159000000000 sodium salts Chemical class 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229920002125 Sokalan® Polymers 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- -1 alkali metal salt Chemical class 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229920000058 polyacrylate Polymers 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229960000530 carbenoxolone Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010017982 Gastrointestinal necrosis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- KRCMKUNIILUXPF-UHFFFAOYSA-N methyl 4-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=C(O)C=C1 KRCMKUNIILUXPF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- WXSLOYPZKHFWII-UHFFFAOYSA-N propyl 4-hydroxybenzoate;sodium Chemical compound [Na].CCCOC(=O)C1=CC=C(O)C=C1 WXSLOYPZKHFWII-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- CKLBXIYTBHXJEH-UHFFFAOYSA-J 75881-23-1 Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cu+2].[N-]1C(N=C2C3=CC=C(CSC(N(C)C)=[N+](C)C)C=C3C(N=C3C4=CC=C(CSC(N(C)C)=[N+](C)C)C=C4C(=N4)[N-]3)=N2)=C(C=C(CSC(N(C)C)=[N+](C)C)C=C2)C2=C1N=C1C2=CC(CSC(N(C)C)=[N+](C)C)=CC=C2C4=N1 CKLBXIYTBHXJEH-UHFFFAOYSA-J 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010070818 Oesophageal irritation Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008142 bulk forming laxative Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Description
ç£æ¥äžã®å©çšåé
æ¬çºæã¯è¬å€çµæç©ã«é¢ãããã詳ããã¯è
çããã³èâåäºæ¯è žæœ°çã®æ²»ççšçµæç©ã«é¢
ããã åŸæ¥ã®æè¡ ããŒãã³ã°ããŒã«ïŒMartindaleïŒãThe
Extra Pharmacopoeia28çã77é ïŒ1982幎ïŒ
ã«ã¯ã«ã«ããããœãã³ãããªãŠã ïŒã°ãªã·ã«ã
ãã³é žããã¹ã¯ã·ããŒãã®äºãããªãŠã å¡©ïŒã
èšèŒãããèãåäºæè žãŸãã¯é£éãããã朰
çã®æ²»ççšã«éçºãããçš®ã ã®è¬å€ã®è©³çŽ°ãäž
ããããŠãããéºæŸã«ããã«ã«ããããœãã³ã
ããªãŠã ã«ããæ²»çã¯äœæ¶²åçããã€è¡æ§å¿äž
å šãé«è¡å§çããã³äœã«ãªãŠã è¡çã®ãããª
çš®ã ã®æ¿ããã®å¯äœçšã䌎ãªãããšãããã匷
åãªãã¹ã¿ãã³H2å容äœæ®æå€ã®éçºãšãšã
ã«æ²»çã¯ã·ã¡ããžã³ïŒcimetidineïŒããã³ã©ã
ããžã³ïŒranitidineïŒã®ãããªè¬å€ã䜿çšãã
åŸåããã€ãã ããªã¢ã¯ãªã«é žãããªãŠã ã¯æ¶åæ§æœ°çã®æ²»
çã«ããã䜿çšã瀺åããããè±åœç¹èš±ç¬¬
1435630å·ã«ã¯ã0.3ãŸãã¯ããé«ãåºæç²åºŠã
æããããªã¢ã¯ãªã«é žãããªãŠã ãšè¬å€äžæŽ»æ§
åºäœæ äœãšãå«ãåºäœææ¶åæ§æœ°ççµæç©ãèš
èŒãããŠãããè±åœç¹èš±ç¬¬15383562å·ã«ã¯æ°Žäž
溶æ§ã§ããã氎浞éæ§ã®ã³ãŒãã€ã³ã°å€ã§è¢«èŠ
ããããªã¢ã¯ãªã«é žã¢ã«ã«ãªéå±å¡©ã®ç²ãå«ã
æ¹è¯çµæç©ãèšèŒãããŠãããé©åœãªããªã¢ã¯
ãªã«é žã¢ã«ã«ãªéå±å¡©ã¯ååé3000000ã
8000000ã®ããªã¢ã¯ãªã«é žãããªãŠã ãå«ããš
ãããããèšèŒã®ç¹å®ã®ããªã¢ã¯ãªã«é žãããª
ãŠã ã¯ååéçŽ3400000ã®ãã®ã§ããã çºæã®æŠèŠ çºæè ãã¯ã«ã«ããããœãã³ãããªãŠã ãã
ã³å€©ç¶ããã³åæèµ·æºã®çš®ã ã®é žéåäœã®ç²è
ä¿è·æ§ã«ã€ããŠç 究ããªã€ããæå€ã«ãã«ã«ã
ãããœãã³ãããªãŠã ãšããªã¢ã¯ãªã«é žãããª
ãŠã ãšãããå²åã§æ··åãããšãã«çžä¹äœçšå¹
æãããããšãèŠåºãããã æ¬çºæã«ããã°ãã«ã«ããããœãã³ãããªãŠ
ã ãšããªã¢ã¯ãªã«é žãããªãŠã ãšãïŒïŒ20ã
ïŒïŒïŒã䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã奜
ãŸããã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã§å«ãè¬å€çµ
æç©ãæäŸãããã ããã«çšãããããªã¢ã¯ãªé žãããªãŠã ãã¯
ç·ç¶ãŸãã¯æ©ããçµåãããŠããã§ãããããª
ã¢ã¯ãªã«ãµã³ã®ãããªãŠã å¡©ãè¡šãããç·ç¶ã
ãªã¢ã¯ãªã©ãŒãã®åæ¥éæã®äŸã¯ã«ã«ããã«
ïŒCarbopolïŒ907ïŒéé¢é žåœ¢ãB.F.ã°ãããªã
ãïŒããã³ã¢ãã³ãã¹ïŒAronvisïŒïŒãããªãŠ
ã å¡©ãæ¥æ¬çŽè¬ïŒã§ãããæ©ããçµåããªã¢ã¯
ãªã«é žãããªãŠã åæ¥éæã®äŸã¯ã¬ãªãžãã¯
ïŒRheogicïŒ252Lãã¬ãªãžãã¯250HïŒæ¥æ¬çŽè¬ïŒ
ããã³ãã¹ã¿ã»ãªã³ïŒHostacerinïŒPN73ïŒã
ãã¹ãU.K.Ltd.ïŒã§ããã奜ãŸããæ©ããçµ
åããªã¢ã¯ãªãªãŒãã¯ã«ã«ãã¡ã«ïŒcarbomerïŒ
ã®ç¯å²ïŒéé¢é žåœ¢æ ïŒã®ãã®ã§ããã çºæã®è©³çŽ° æ¬çºæã®å¥œãŸãã芳ç¹ã«ãããŠãã«ã«ããã
ãœãã³ãããªãŠã ãšã«ã«ãã¡ã«ãããªãŠã ã
ïŒïŒ20ãïŒïŒïŒã䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®é
éæ¯ã奜ãŸããã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã§å«
ãè¬å€çµæç©ãæäŸãããã ã«ã«ãã¡ã«ã¯è±åœè¬å±æ¹ããã³ç±³åœåœæ°å»è¬
åéã«ã«ã«ãã³é žåº56ã68ïŒ ãå«æããã¢ã¯ãª
ã«é žã®åæé«ååéæ©ããéåäœã§ãããšèšèŒ
ããããè±åœè¬å±æ¹ã¯ã¢ãªã«ã¹ã¯ããŒã¹ã«ãã
æ©ããçµåãç¹å®ãããã«ã«ãã¡ã«ã¯äžåã²ã«
ã®åœ¢æ ã§ãå æããã³å€çšçšè£œå€äžã«æžæ¿å€ãš
ããŠäœ¿çšããããç±³åœç¹èš±ç¬¬2909462å·ã«ã¯çŽ
0.75ã2.0ïŒ ã®ããªã¢ãªã«ã¹ã¯ããŒã¹ã§æ©ãã
çµåããã¢ã¯ãªã«é žã®ã³ãã€ãæ§æ°Žæº¶æ§éåäœ
ã®ãã«ã¯ç·©äžå€ãšããŠã®äœ¿çšãèšèŒãããã ã«ã«ãã¡ã«ã®é©åœãªåæ¥éæã®äŸã¯ç»é²åæš
ã«ã«ããã«910ã934ã934Pã940ããã³941ã§
B.F.ã°ãããªãããã販売ããããã®ã§ããã
ä»ã®äŸã¯ãžãŠã³ãã³ïŒJunlonïŒPW110ããžãŠ
ã³ãã³PW150ããã³ãžãŠã³ãã³PW111ãšããŠ
æ¥æ¬çŽè¬ã«ãã販売ããããã®ãããã³ã¢ã¯ãª
ã·ã³ãïŒAcrisintïŒ400ïŒã·ã°ããã€ã¿ãªãŒïŒã§
ãããæ¬çºæã®çµæç©ã«ãããŠã奜ãŸããç©è³ª
çŽ3000000ã®ååéãæããã«ã«ãã¡ã«934Pã§
ãããåæ¥éæã¯ã«ã«ããã«934Pã§ãã
ãUSANããã³è¬å€åã®ç±³åœè¬å±æ³ïŒUSPïŒèŸ
å žãUSAN1984ã89é åç §ãã æ¬çºæã®çµæç©ã¯çµå£æäžçšã§ããã奜ãŸã
ãã¯7.5ã9.5ã®PHãæããæ°Žæ§çµæç©ã®åœ¢æ ã§
ãããçšããããªã¢ã¯ãªã©ãŒããé žåœ¢æ ã§ãã
ã°ã補é å·¥çšäžã«ãããªãŠã 圢ã«è»¢åãããã æ¬çºæã¯ãŸãã¯ã«ã«ããããœãã³ãããªãŠã
ãšããªã¢ã¯ãªã«é žãããªãŠã ãšãïŒïŒ20ãïŒïŒ
ïŒã䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã奜ãŸã
ãã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã§èçãŸãã¯èâ
åäºæ¯è žæœ°çã®æ²»çã«ããã䜿çšãå å«ããã èçãŸãã¯èâåäºæ¯è žæœ°çã®æ²»çã«ãã
ãŠãã«ã«ããããœãã³ãããªãŠã ãšããªã¢ã¯ãª
ã«é žãããªãŠã ãšã®ééæ¯ãïŒïŒ20ãïŒïŒïŒã
䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®ç¯å²ã«å ¥ããŠãã«ã«
ããããœãã³ãããªãŠã ã®éåžžæè¬éã¯40ãïŒ
mgã®ç¯å²ã§ãããããªã¢ã¯ãªã«é žãããªãŠã ã®
æè¬éã¯200ãïŒmgã®ç¯å²ã§ããã ã«ã«ããããœãã³ãããªãŠã ãšããªã¢ã¯ãªã«
é žãããªãŠã ãšã®éã®çžä¹äœçšå¹æã®ããã«ã
æ¬çµæç©ã¯äœ¿çšãããã«ã«ããããœãã³ãããª
ãŠã ã®äžå±€äœãçšéã®å¯èœæ§ãäžãããã®çµæ
å¯äœçšãäœäžããã çµæç©ã¯ãŸãå¶é žå€ãå«ãããšãã§ãããé©
åœãªç©è³ªã«ã¯çé žæ°ŽçŽ ãããªãŠã ãçé žã«ã«ã·
ãŠã ãæ°Žé žåã¢ã«ãããŠã ãããã³ãããã®æ··
åç©ãå«ãŸããããããã®ç©è³ªãæ®ã«çé žæ°ŽçŽ
ãããªãŠã ãã®äœ¿çšã¯ãŸãã液äœçµæç©ã®ç²åºŠ
ãäœäžãããããã«ããææ³šå ¥æ§æ¶²äœè£œå€ã®èš
èšã«ãããŠããçšåºŠã®ç²åºŠå¶åŸ¡ãäžããã é£éã®ççãŸãã¯æœ°çãçããéšåã®æ²»çã«
ã¯ãçµæç©ã¯å¥œãŸãããŸããã¢ã«ã®ã³é žãããª
ãŠã ãçé žã«ã«ã·ãŠã ããã³çé žæ°ŽçŽ ãããªãŠ
ã ãšãšãã«å«ããçºæè ã®è±åœç¹èš±ç¬¬1524740
å·ã«ã¯äœç²åºŠéæã®ã¢ã«ã®ã³é žãããªãŠã ïŒç€º
ãããããªïŒãã¢ã«ã®ã³é žãããªãŠã ã®ééåœ
ã0.16ã2.60éééšã®çé žæ°ŽçŽ ãããªãŠã ãã
ã³ã¢ã«ã®ã³é žãããªãŠã ã®ééåœã0.10ã1.04
éééšã®çé žã«ã«ã·ãŠã ãå«ãè¬å€çµæç©ãèš
èŒãããç¹èš±è«æ±ãããŠããããã®ç¹èš±ã«èšèŒ
ã®çµæç©ãèé žã«æ¥è§Šãããšãã¢ã«ã®ã³é žã®æ¯
èŒç硬ããŒã©ãã³ç¶æ²æŸ±ã圢æããããçµæç©
äžã«ååšããçé žæ°ŽçŽ ãããªãŠã ããã³çé žã«
ã«ã·ãŠã ã¯èé žãšåå¿ããŠäºé žåççŽ ãçãã
ãããã²ã«äžã«éã蟌ãããããäœãããå¯åºŠ
ãæããçé žåã²ã«ã¯æ¬¡ãã§èé žè¡šé¢ã«æµ®ã
ã³ãã«ã«ã·ãŠã ã€ãªã³ã¯æ²æŸ±ããã¢ã«ã®ã³é žå
åãæ©ããããã²ã«ãããªãã¯ã¹ã匷åããäœ
çšããããèé žéæµãèµ·ããšäœå¯åºŠçé žåã²ã«
ãé£éã®äžéšäžãžé²ã¿ããã®ççãŸãã¯æœ°çã
çããéšåã«æ¥è§Šãããæ¬çºæã®ã«ã«ããããœ
ãã³ãããªãŠã ãšããªã¢ã¯ãªã«é žãããªãŠã ãš
ã®çžä¹äœçšççµåãã¯ãè±åœç¹èš±ç¬¬1524740å·
ã®çµæç©ã«çµèŸŒãŸãããšéæµããçé žåã²ã«ã
çžä¹äœçšæ··åç©ãé£éã®ççãŸãã¯æœ°çãçã
ãéšåãžééããã æ±æããã³åŸã®åŸ®çç©ã«ããæªåããããã
ãæ°Žæ§çµæç©ã§ã¯ä¿åå€ãå å«ãããããšã奜
ãŸãããé©åœãªç³»ã¯ã¡ãã«âããã³ãããã«â
ïœâããããã·ãã³ãŸã¢ãŒããŸãã¯ãããã®ã
ããªãŠã å¡©ã®çµåãã§ããã æ¬çºæã®è¬å€çµæç©ã¯ãŸãçè²å€ãçå³å€ãŸ
ãã¯è³éŠå€ã®ïŒã€ãŸãã¯ããå€ããå«ãããšã
ã§ããã æ¬çºæã¯æ¬¡ã®å®æœäŸã«ããäŸç€ºãããã å®æœäŸ ïŒ æ¬¡ã®é åãæãã液äœè£œå€ã補é ããïŒ ã«ã«ããããœãã³ãããªãŠã 0.20ïœ ã«ã«ããã« 934P 0.42ïœ çé žæ°ŽçŽ ãããªãŠã 2.67ïœ ã¡ãã«ïœâããããã·ãã³ãŸã¢ãŒã 0.40ïœ ãããã«ïœâããããã·ãã³ãŸã¢ãŒã 0.06ïœ æ°Žé žåãããªãŠã 0.18ïœ çè²ãè³éŠãçå³å€ 0.10ïœ æ°Ž
100.00mlãŸã§ã«ã«ããã«ãæ°ŽçŽ40mläžã«ãããŸ
ããªããåæ£ãã次ãã§æ°Žé žåãããªãŠã 氎溶
液ãå ãããšã²ã«ãäžãããå¥ã®å®¹åšäžã§æ°ŽçŽ
50mlã«ã«ã«ããããœãã³ãããªãŠã ãçé žæ°ŽçŽ
ãããªãŠã ãã¡ãã«âããã³ãããã«âïœâã
ãããã·ãã³ãŸã¢ãŒãããããŸããªããå ã
ãã次ãã§ãã®æ··åç©ã«ã«ã«ããã«ã²ã«ãå ã
ãŠååã«æ··åããã次ãã§çè²ãè³éŠããã³ç
å³å€ãå ãã次ã«æ°Žãå ããŠ100mlã®å®¹éã«ã
ãã補å€ã¯PHïŒ7.8ãæããã å®æœäŸ ïŒ çé žã«ã«ã·ãŠã 1.60ïœããã³ã¢ã«ã®ã³é žãã
ãªãŠã ãããã¿ãã«ïŒProntnalïŒïŒç»é²åæš
LF5ïŒ60ãããã¿ã³ïŒãã¢ã²ã¿ã³ããã«ãŠãš
ãŒã6.00ïœã®æ·»å ã«ããå®æœäŸïŒã®è£œå€ã®é å
ãå€ããã補å€ã¯å®æœäŸïŒãšåæ§ã®æé ã«ãã
補é ãããïŒã€ã®è¿œå æåã¯ã«ã«ããããœãã³
ãããªãŠã ãçé žæ°ŽçŽ ãããªãŠã ãã¡ãã«ãã
ã³ãããã«âïœâããããã·ãã³ãŸã¢ãŒãã«æ··
åããã å®æœäŸïŒãïŒ äžèšã¯å®æœäŸïŒèšèŒã®æ¹æ³ã«ãã補é ããä»
ã®é åç©ã®è©³çŽ°ã§ãããåå®æœäŸã¯ã«ã«ããã
ãœãã³ãããªãŠã 0.20ïœãã¡ãã«ïœâãããã
ã·ãã³ãŸã¢ãŒããããªãŠã 0.149ïœããããã«
ïœâããããã·ãã³ãŸã¢ãŒããããªãŠã 0.022
ïœããã³100mlãŸã§ã®æ°Žãå«æããã
çããã³èâåäºæ¯è žæœ°çã®æ²»ççšçµæç©ã«é¢
ããã åŸæ¥ã®æè¡ ããŒãã³ã°ããŒã«ïŒMartindaleïŒãThe
Extra Pharmacopoeia28çã77é ïŒ1982幎ïŒ
ã«ã¯ã«ã«ããããœãã³ãããªãŠã ïŒã°ãªã·ã«ã
ãã³é žããã¹ã¯ã·ããŒãã®äºãããªãŠã å¡©ïŒã
èšèŒãããèãåäºæè žãŸãã¯é£éãããã朰
çã®æ²»ççšã«éçºãããçš®ã ã®è¬å€ã®è©³çŽ°ãäž
ããããŠãããéºæŸã«ããã«ã«ããããœãã³ã
ããªãŠã ã«ããæ²»çã¯äœæ¶²åçããã€è¡æ§å¿äž
å šãé«è¡å§çããã³äœã«ãªãŠã è¡çã®ãããª
çš®ã ã®æ¿ããã®å¯äœçšã䌎ãªãããšãããã匷
åãªãã¹ã¿ãã³H2å容äœæ®æå€ã®éçºãšãšã
ã«æ²»çã¯ã·ã¡ããžã³ïŒcimetidineïŒããã³ã©ã
ããžã³ïŒranitidineïŒã®ãããªè¬å€ã䜿çšãã
åŸåããã€ãã ããªã¢ã¯ãªã«é žãããªãŠã ã¯æ¶åæ§æœ°çã®æ²»
çã«ããã䜿çšã瀺åããããè±åœç¹èš±ç¬¬
1435630å·ã«ã¯ã0.3ãŸãã¯ããé«ãåºæç²åºŠã
æããããªã¢ã¯ãªã«é žãããªãŠã ãšè¬å€äžæŽ»æ§
åºäœæ äœãšãå«ãåºäœææ¶åæ§æœ°ççµæç©ãèš
èŒãããŠãããè±åœç¹èš±ç¬¬15383562å·ã«ã¯æ°Žäž
溶æ§ã§ããã氎浞éæ§ã®ã³ãŒãã€ã³ã°å€ã§è¢«èŠ
ããããªã¢ã¯ãªã«é žã¢ã«ã«ãªéå±å¡©ã®ç²ãå«ã
æ¹è¯çµæç©ãèšèŒãããŠãããé©åœãªããªã¢ã¯
ãªã«é žã¢ã«ã«ãªéå±å¡©ã¯ååé3000000ã
8000000ã®ããªã¢ã¯ãªã«é žãããªãŠã ãå«ããš
ãããããèšèŒã®ç¹å®ã®ããªã¢ã¯ãªã«é žãããª
ãŠã ã¯ååéçŽ3400000ã®ãã®ã§ããã çºæã®æŠèŠ çºæè ãã¯ã«ã«ããããœãã³ãããªãŠã ãã
ã³å€©ç¶ããã³åæèµ·æºã®çš®ã ã®é žéåäœã®ç²è
ä¿è·æ§ã«ã€ããŠç 究ããªã€ããæå€ã«ãã«ã«ã
ãããœãã³ãããªãŠã ãšããªã¢ã¯ãªã«é žãããª
ãŠã ãšãããå²åã§æ··åãããšãã«çžä¹äœçšå¹
æãããããšãèŠåºãããã æ¬çºæã«ããã°ãã«ã«ããããœãã³ãããªãŠ
ã ãšããªã¢ã¯ãªã«é žãããªãŠã ãšãïŒïŒ20ã
ïŒïŒïŒã䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã奜
ãŸããã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã§å«ãè¬å€çµ
æç©ãæäŸãããã ããã«çšãããããªã¢ã¯ãªé žãããªãŠã ãã¯
ç·ç¶ãŸãã¯æ©ããçµåãããŠããã§ãããããª
ã¢ã¯ãªã«ãµã³ã®ãããªãŠã å¡©ãè¡šãããç·ç¶ã
ãªã¢ã¯ãªã©ãŒãã®åæ¥éæã®äŸã¯ã«ã«ããã«
ïŒCarbopolïŒ907ïŒéé¢é žåœ¢ãB.F.ã°ãããªã
ãïŒããã³ã¢ãã³ãã¹ïŒAronvisïŒïŒãããªãŠ
ã å¡©ãæ¥æ¬çŽè¬ïŒã§ãããæ©ããçµåããªã¢ã¯
ãªã«é žãããªãŠã åæ¥éæã®äŸã¯ã¬ãªãžãã¯
ïŒRheogicïŒ252Lãã¬ãªãžãã¯250HïŒæ¥æ¬çŽè¬ïŒ
ããã³ãã¹ã¿ã»ãªã³ïŒHostacerinïŒPN73ïŒã
ãã¹ãU.K.Ltd.ïŒã§ããã奜ãŸããæ©ããçµ
åããªã¢ã¯ãªãªãŒãã¯ã«ã«ãã¡ã«ïŒcarbomerïŒ
ã®ç¯å²ïŒéé¢é žåœ¢æ ïŒã®ãã®ã§ããã çºæã®è©³çŽ° æ¬çºæã®å¥œãŸãã芳ç¹ã«ãããŠãã«ã«ããã
ãœãã³ãããªãŠã ãšã«ã«ãã¡ã«ãããªãŠã ã
ïŒïŒ20ãïŒïŒïŒã䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®é
éæ¯ã奜ãŸããã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã§å«
ãè¬å€çµæç©ãæäŸãããã ã«ã«ãã¡ã«ã¯è±åœè¬å±æ¹ããã³ç±³åœåœæ°å»è¬
åéã«ã«ã«ãã³é žåº56ã68ïŒ ãå«æããã¢ã¯ãª
ã«é žã®åæé«ååéæ©ããéåäœã§ãããšèšèŒ
ããããè±åœè¬å±æ¹ã¯ã¢ãªã«ã¹ã¯ããŒã¹ã«ãã
æ©ããçµåãç¹å®ãããã«ã«ãã¡ã«ã¯äžåã²ã«
ã®åœ¢æ ã§ãå æããã³å€çšçšè£œå€äžã«æžæ¿å€ãš
ããŠäœ¿çšããããç±³åœç¹èš±ç¬¬2909462å·ã«ã¯çŽ
0.75ã2.0ïŒ ã®ããªã¢ãªã«ã¹ã¯ããŒã¹ã§æ©ãã
çµåããã¢ã¯ãªã«é žã®ã³ãã€ãæ§æ°Žæº¶æ§éåäœ
ã®ãã«ã¯ç·©äžå€ãšããŠã®äœ¿çšãèšèŒãããã ã«ã«ãã¡ã«ã®é©åœãªåæ¥éæã®äŸã¯ç»é²åæš
ã«ã«ããã«910ã934ã934Pã940ããã³941ã§
B.F.ã°ãããªãããã販売ããããã®ã§ããã
ä»ã®äŸã¯ãžãŠã³ãã³ïŒJunlonïŒPW110ããžãŠ
ã³ãã³PW150ããã³ãžãŠã³ãã³PW111ãšããŠ
æ¥æ¬çŽè¬ã«ãã販売ããããã®ãããã³ã¢ã¯ãª
ã·ã³ãïŒAcrisintïŒ400ïŒã·ã°ããã€ã¿ãªãŒïŒã§
ãããæ¬çºæã®çµæç©ã«ãããŠã奜ãŸããç©è³ª
çŽ3000000ã®ååéãæããã«ã«ãã¡ã«934Pã§
ãããåæ¥éæã¯ã«ã«ããã«934Pã§ãã
ãUSANããã³è¬å€åã®ç±³åœè¬å±æ³ïŒUSPïŒèŸ
å žãUSAN1984ã89é åç §ãã æ¬çºæã®çµæç©ã¯çµå£æäžçšã§ããã奜ãŸã
ãã¯7.5ã9.5ã®PHãæããæ°Žæ§çµæç©ã®åœ¢æ ã§
ãããçšããããªã¢ã¯ãªã©ãŒããé žåœ¢æ ã§ãã
ã°ã補é å·¥çšäžã«ãããªãŠã 圢ã«è»¢åãããã æ¬çºæã¯ãŸãã¯ã«ã«ããããœãã³ãããªãŠã
ãšããªã¢ã¯ãªã«é žãããªãŠã ãšãïŒïŒ20ãïŒïŒ
ïŒã䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã奜ãŸã
ãã¯ïŒïŒïŒãïŒïŒïŒã®ééæ¯ã§èçãŸãã¯èâ
åäºæ¯è žæœ°çã®æ²»çã«ããã䜿çšãå å«ããã èçãŸãã¯èâåäºæ¯è žæœ°çã®æ²»çã«ãã
ãŠãã«ã«ããããœãã³ãããªãŠã ãšããªã¢ã¯ãª
ã«é žãããªãŠã ãšã®ééæ¯ãïŒïŒ20ãïŒïŒïŒã
䟿å®ã«ã¯ïŒïŒïŒãïŒïŒïŒã®ç¯å²ã«å ¥ããŠãã«ã«
ããããœãã³ãããªãŠã ã®éåžžæè¬éã¯40ãïŒ
mgã®ç¯å²ã§ãããããªã¢ã¯ãªã«é žãããªãŠã ã®
æè¬éã¯200ãïŒmgã®ç¯å²ã§ããã ã«ã«ããããœãã³ãããªãŠã ãšããªã¢ã¯ãªã«
é žãããªãŠã ãšã®éã®çžä¹äœçšå¹æã®ããã«ã
æ¬çµæç©ã¯äœ¿çšãããã«ã«ããããœãã³ãããª
ãŠã ã®äžå±€äœãçšéã®å¯èœæ§ãäžãããã®çµæ
å¯äœçšãäœäžããã çµæç©ã¯ãŸãå¶é žå€ãå«ãããšãã§ãããé©
åœãªç©è³ªã«ã¯çé žæ°ŽçŽ ãããªãŠã ãçé žã«ã«ã·
ãŠã ãæ°Žé žåã¢ã«ãããŠã ãããã³ãããã®æ··
åç©ãå«ãŸããããããã®ç©è³ªãæ®ã«çé žæ°ŽçŽ
ãããªãŠã ãã®äœ¿çšã¯ãŸãã液äœçµæç©ã®ç²åºŠ
ãäœäžãããããã«ããææ³šå ¥æ§æ¶²äœè£œå€ã®èš
èšã«ãããŠããçšåºŠã®ç²åºŠå¶åŸ¡ãäžããã é£éã®ççãŸãã¯æœ°çãçããéšåã®æ²»çã«
ã¯ãçµæç©ã¯å¥œãŸãããŸããã¢ã«ã®ã³é žãããª
ãŠã ãçé žã«ã«ã·ãŠã ããã³çé žæ°ŽçŽ ãããªãŠ
ã ãšãšãã«å«ããçºæè ã®è±åœç¹èš±ç¬¬1524740
å·ã«ã¯äœç²åºŠéæã®ã¢ã«ã®ã³é žãããªãŠã ïŒç€º
ãããããªïŒãã¢ã«ã®ã³é žãããªãŠã ã®ééåœ
ã0.16ã2.60éééšã®çé žæ°ŽçŽ ãããªãŠã ãã
ã³ã¢ã«ã®ã³é žãããªãŠã ã®ééåœã0.10ã1.04
éééšã®çé žã«ã«ã·ãŠã ãå«ãè¬å€çµæç©ãèš
èŒãããç¹èš±è«æ±ãããŠããããã®ç¹èš±ã«èšèŒ
ã®çµæç©ãèé žã«æ¥è§Šãããšãã¢ã«ã®ã³é žã®æ¯
èŒç硬ããŒã©ãã³ç¶æ²æŸ±ã圢æããããçµæç©
äžã«ååšããçé žæ°ŽçŽ ãããªãŠã ããã³çé žã«
ã«ã·ãŠã ã¯èé žãšåå¿ããŠäºé žåççŽ ãçãã
ãããã²ã«äžã«éã蟌ãããããäœãããå¯åºŠ
ãæããçé žåã²ã«ã¯æ¬¡ãã§èé žè¡šé¢ã«æµ®ã
ã³ãã«ã«ã·ãŠã ã€ãªã³ã¯æ²æŸ±ããã¢ã«ã®ã³é žå
åãæ©ããããã²ã«ãããªãã¯ã¹ã匷åããäœ
çšããããèé žéæµãèµ·ããšäœå¯åºŠçé žåã²ã«
ãé£éã®äžéšäžãžé²ã¿ããã®ççãŸãã¯æœ°çã
çããéšåã«æ¥è§Šãããæ¬çºæã®ã«ã«ããããœ
ãã³ãããªãŠã ãšããªã¢ã¯ãªã«é žãããªãŠã ãš
ã®çžä¹äœçšççµåãã¯ãè±åœç¹èš±ç¬¬1524740å·
ã®çµæç©ã«çµèŸŒãŸãããšéæµããçé žåã²ã«ã
çžä¹äœçšæ··åç©ãé£éã®ççãŸãã¯æœ°çãçã
ãéšåãžééããã æ±æããã³åŸã®åŸ®çç©ã«ããæªåããããã
ãæ°Žæ§çµæç©ã§ã¯ä¿åå€ãå å«ãããããšã奜
ãŸãããé©åœãªç³»ã¯ã¡ãã«âããã³ãããã«â
ïœâããããã·ãã³ãŸã¢ãŒããŸãã¯ãããã®ã
ããªãŠã å¡©ã®çµåãã§ããã æ¬çºæã®è¬å€çµæç©ã¯ãŸãçè²å€ãçå³å€ãŸ
ãã¯è³éŠå€ã®ïŒã€ãŸãã¯ããå€ããå«ãããšã
ã§ããã æ¬çºæã¯æ¬¡ã®å®æœäŸã«ããäŸç€ºãããã å®æœäŸ ïŒ æ¬¡ã®é åãæãã液äœè£œå€ã補é ããïŒ ã«ã«ããããœãã³ãããªãŠã 0.20ïœ ã«ã«ããã« 934P 0.42ïœ çé žæ°ŽçŽ ãããªãŠã 2.67ïœ ã¡ãã«ïœâããããã·ãã³ãŸã¢ãŒã 0.40ïœ ãããã«ïœâããããã·ãã³ãŸã¢ãŒã 0.06ïœ æ°Žé žåãããªãŠã 0.18ïœ çè²ãè³éŠãçå³å€ 0.10ïœ æ°Ž
100.00mlãŸã§ã«ã«ããã«ãæ°ŽçŽ40mläžã«ãããŸ
ããªããåæ£ãã次ãã§æ°Žé žåãããªãŠã 氎溶
液ãå ãããšã²ã«ãäžãããå¥ã®å®¹åšäžã§æ°ŽçŽ
50mlã«ã«ã«ããããœãã³ãããªãŠã ãçé žæ°ŽçŽ
ãããªãŠã ãã¡ãã«âããã³ãããã«âïœâã
ãããã·ãã³ãŸã¢ãŒãããããŸããªããå ã
ãã次ãã§ãã®æ··åç©ã«ã«ã«ããã«ã²ã«ãå ã
ãŠååã«æ··åããã次ãã§çè²ãè³éŠããã³ç
å³å€ãå ãã次ã«æ°Žãå ããŠ100mlã®å®¹éã«ã
ãã補å€ã¯PHïŒ7.8ãæããã å®æœäŸ ïŒ çé žã«ã«ã·ãŠã 1.60ïœããã³ã¢ã«ã®ã³é žãã
ãªãŠã ãããã¿ãã«ïŒProntnalïŒïŒç»é²åæš
LF5ïŒ60ãããã¿ã³ïŒãã¢ã²ã¿ã³ããã«ãŠãš
ãŒã6.00ïœã®æ·»å ã«ããå®æœäŸïŒã®è£œå€ã®é å
ãå€ããã補å€ã¯å®æœäŸïŒãšåæ§ã®æé ã«ãã
補é ãããïŒã€ã®è¿œå æåã¯ã«ã«ããããœãã³
ãããªãŠã ãçé žæ°ŽçŽ ãããªãŠã ãã¡ãã«ãã
ã³ãããã«âïœâããããã·ãã³ãŸã¢ãŒãã«æ··
åããã å®æœäŸïŒãïŒ äžèšã¯å®æœäŸïŒèšèŒã®æ¹æ³ã«ãã補é ããä»
ã®é åç©ã®è©³çŽ°ã§ãããåå®æœäŸã¯ã«ã«ããã
ãœãã³ãããªãŠã 0.20ïœãã¡ãã«ïœâãããã
ã·ãã³ãŸã¢ãŒããããªãŠã 0.149ïœããããã«
ïœâããããã·ãã³ãŸã¢ãŒããããªãŠã 0.022
ïœããã³100mlãŸã§ã®æ°Žãå«æããã
ãè¡šã
å®æœäŸ10ã15
ããã«ä»¥äžã®å®æœäŸãå®æœäŸïŒèšèŒã®æ¹æ³ã«
ãã補é ãããåå®æœäŸã¯ã«ã«ããã«934P1.0
ïœãæ°Žé žåãããªãŠã 0.43ïœãã¡ãã«ïœâãã
ããã·ãã³ãŸã¢ãŒããããªãŠã 0.149ïœããã
ãã«ïœâããããã·ãã³ãŸã¢ãŒããããªãŠã
0.022ïœãçè²ãè³éŠãããã³çå³å€0.1ïœäžŠã³
ã«100mlãŸã§ã®æ°Žãå«æããã
ãã補é ãããåå®æœäŸã¯ã«ã«ããã«934P1.0
ïœãæ°Žé žåãããªãŠã 0.43ïœãã¡ãã«ïœâãã
ããã·ãã³ãŸã¢ãŒããããªãŠã 0.149ïœããã
ãã«ïœâããããã·ãã³ãŸã¢ãŒããããªãŠã
0.022ïœãçè²ãè³éŠãããã³çå³å€0.1ïœäžŠã³
ã«100mlãŸã§ã®æ°Žãå«æããã
ãè¡šã
å®æœäŸ 16
次ã®çµæãæãã液äœè£œå€ãå®æœäŸïŒèšèŒã®
æ¹æ³ã«ãã補é ããïŒ ã«ã«ããããœãã³ãããªãŠã 0.20ïœ ã«ã«ããã« 910P 2.00ïœ çé žæ°ŽçŽ ãããªãŠã 1.00ïœ ã¡ãã«ïœâããããã·ãã³ãŸã¢ãŒã 0.149ïœ ãããã«ïœâããããã·ãã³ãŸã¢ãŒã
0.022ïœ æ°Žé žåãããªãŠã 0.86ïœ çè²ãè³éŠãçå³å€ 0.10ïœ æ°Ž 100.00mlãŸã§ PHïŒ8.3 å®æœäŸ 17 ç¡æ°Žã¡ã¿ããŒã«3.6Kgäžã®æ°Žé žåãããªãŠã
400ïœã®æ¶²äœã«ã«ã«ããã«934P1Kgãåæ£ãã
ããšã«ããã«ã«ããã«934PãããªãŠã å¡©ã補
é ããããã®å¡©ãæ¿Ÿéã«ããæéãã也ç¥ãã
ç²æ«ã«ããã ã«ã«ããã«934PãããªãŠã å¡©750ïœãã«ã«ã
ãããœãã³ãããªãŠã 150ïœããã³ç²æ«ã©ã¯ã
ãŒã¹1350ïœãšé åãããç²æ«é åç©ãéæ圢ã
ããµãŒäžã§ã€ãœãããããŒã«äžã®ããªããã«ã
ããªãã³ããããã³ïŒpovidoneïŒK30ãã®10ïŒ
ïŒïŒ¶æº¶æ¶²1.5ãšæ··åãã湿最å¡750ÎŒïœã¹ã¯
ãªãŒã³ãåãä»ããæ¯åé ç²æ©ã«éããã ç²ã也ç¥ã750ÎŒïœãµããã«éããã ããããã«ã«ããã«934PãããªãŠã å¡©100mg
ããã³ã«ã«ããããœãã³ãããªãŠã 20mgãå«æ
ãããããã®ç²å320mgåäœããµã€ãºïŒç¡¬è³ªãŒ
ã©ãã³ã«ãã»ã«ã«å ãŠãããã å®æœäŸ 18 ã«ã«ããã«934PãããªãŠã å¡©250ïœãã«ã«ã
ãããœãã³ãããªãŠã 50ïœããã³ã©ã¯ããŒã¹
2.5Kgãšé åãããç²æ«ãéæ圢ãããµãŒäžã§
ã€ãœãããããŒã«äžã®ããªããã«ãããªãã³
ããããã³K30ãã®20ïŒ ïŒ·ïŒïŒ¶æº¶æ¶²1.75ãšæ··
åãã湿最å¡ãæ¯åé ç²æ©äžã®750ÎŒïœã¹ã¯ãª
ãŒã³ã«éãããç²ã也ç¥ããåã³750ÎŒïœãµã
ãã«éããã åã«ã«ããã«934PãããªãŠã å¡©100mgããã³
ã«ã«ããããœãã³ãããªãŠã 20mgãå«æããã
ããã®ç²åã®1.26ïœåäœãã©ãããŒããµãã·ãš
ã«å ãŠãããããµãã·ãšã®å 容ç©ã¯æäžåã«æ°Ž
ïŒå¥œãŸããã¯20ã100mlïŒãšæ··åãããã æ¬çºæã®çµæç©ã®è¬å€ç¹æ§ã¯ïŒã€ã®in vivo
ã©ããã¢ãã«ã§è©äŸ¡ããã æ朰çãŸãã¯ç²èä¿è·æ§ããããŒãä»
ïŒRobert A.ïŒNezamis J.E.ïŒLancasster C.
and Hancher A.J.ïŒïŒGastroenterologyïŒ77ã
433ãïŒ1979ïŒã«ãããšã¿ããŒã«èªçºèå£æ»è©Šéš
ã§æž¬å®ããã ãã®è©Šéšæ³ã«ãããŠãéã¹ãã©ãŒã°ããŒã¬ã€
ïŒSpraueâDawleyïŒã©ããïŒ150ã170ïœïŒã
ïŒå¹ãã€å ¥ããåŠçœ®å18æé絶é£ãããïŒæé
æ°Žã奪ã€ããè¬å€ãŸãã¯è¬å€ããã¯ã«ãïŒmlïŒ
Kgã®çšééã§çµå£çã«æäžããïŒæ¯çŸ€ïœïŒ10ïŒïŒ
30ååŸã©ããã«80ïŒ ãšã¿ããŒã«ãçµå£æçšãã
ãïŒçšééïŒmlïŒKgïŒãïŒæéåŸã©ãããé éš
æµ®ãã€ã¹ãã±ãŒã·ãšã³ïŒcerrical dislocationïŒ
ã«ãã殺ãããçŽã¡ã«è ¹éšãéãèãé²åºãã
ãã èãé£éã®åºéšã§çµçŽ®ãã次ãã§åäºæ¯è žïŒ
ãïŒcmãšãšãã«åãåºãããèå 容ç©ãæ°Žã§ïŒ
åæŽæµãã次ãã§èã70ïŒ ïŒå·¥æ¥å€æ§ã¢ã«ã³ãŒ
ã«ïŒãçšããŠèšåŒµããè©Šéšåã«70ïŒ IMSäžã«ä¿
åãããèã倧匯沿ãã«éããæäžåŠçãç¥ã
ãªã芳å¯è ã«ããç²èãè©Šéšããããç å€ãèŠ
åçãªæ¹æ³ã§ããªã¡ãŒãã«ã§æž¬å®ããé·ããèš
é²ããèåœãã®å šç å€é·ã決å®ããããã¹ãŠã®
èãè©ŠéšããåŸã³ãŒãã解ããç å€æå·ã®ã²ã©
ããã©ããã®çŸ€åœãå¹³åç å€é·ïŒÂ±SEMïŒãš
ããŠè¡šããããããŒã¿ã®çµ±èšåæã¯ç¡å¯ŸããŒã¿
ã«å¯Ÿããã¹ããŠãŒãã³ããïœãè©ŠéšãçšããŠè¡
ãªã€ããååŠçå¹æã¯ïœå€ã0.05æªæºã§ããã°
ææãšæãããã察象ã®ããã¯ã«åŠç矀平åã
è¬å€åŠç矀ãšæ¯èŒãããšã¿ããŒã«ã«ããçãã
ç å€æœ°çããã®ä¿è·çã決å®ããã è¡šïŒã¯ã«ã«ããããœãã³ïŒãããªãŠã å¡©ïŒãŸ
ãã¯ã«ã«ããã«934PïŒãããªãŠã å¡©ïŒå«æãã
PH8.0ãæããçµæç©ã§åŸãããè©ŠéšããŒã¿ã
瀺ããè¡šïŒã¯æåã®å€åéãå«æããPH8.0ã®
çµæç©ã«å¯ŸããããŒã¿ã瀺ãã
æ¹æ³ã«ãã補é ããïŒ ã«ã«ããããœãã³ãããªãŠã 0.20ïœ ã«ã«ããã« 910P 2.00ïœ çé žæ°ŽçŽ ãããªãŠã 1.00ïœ ã¡ãã«ïœâããããã·ãã³ãŸã¢ãŒã 0.149ïœ ãããã«ïœâããããã·ãã³ãŸã¢ãŒã
0.022ïœ æ°Žé žåãããªãŠã 0.86ïœ çè²ãè³éŠãçå³å€ 0.10ïœ æ°Ž 100.00mlãŸã§ PHïŒ8.3 å®æœäŸ 17 ç¡æ°Žã¡ã¿ããŒã«3.6Kgäžã®æ°Žé žåãããªãŠã
400ïœã®æ¶²äœã«ã«ã«ããã«934P1Kgãåæ£ãã
ããšã«ããã«ã«ããã«934PãããªãŠã å¡©ã補
é ããããã®å¡©ãæ¿Ÿéã«ããæéãã也ç¥ãã
ç²æ«ã«ããã ã«ã«ããã«934PãããªãŠã å¡©750ïœãã«ã«ã
ãããœãã³ãããªãŠã 150ïœããã³ç²æ«ã©ã¯ã
ãŒã¹1350ïœãšé åãããç²æ«é åç©ãéæ圢ã
ããµãŒäžã§ã€ãœãããããŒã«äžã®ããªããã«ã
ããªãã³ããããã³ïŒpovidoneïŒK30ãã®10ïŒ
ïŒïŒ¶æº¶æ¶²1.5ãšæ··åãã湿最å¡750ÎŒïœã¹ã¯
ãªãŒã³ãåãä»ããæ¯åé ç²æ©ã«éããã ç²ã也ç¥ã750ÎŒïœãµããã«éããã ããããã«ã«ããã«934PãããªãŠã å¡©100mg
ããã³ã«ã«ããããœãã³ãããªãŠã 20mgãå«æ
ãããããã®ç²å320mgåäœããµã€ãºïŒç¡¬è³ªãŒ
ã©ãã³ã«ãã»ã«ã«å ãŠãããã å®æœäŸ 18 ã«ã«ããã«934PãããªãŠã å¡©250ïœãã«ã«ã
ãããœãã³ãããªãŠã 50ïœããã³ã©ã¯ããŒã¹
2.5Kgãšé åãããç²æ«ãéæ圢ãããµãŒäžã§
ã€ãœãããããŒã«äžã®ããªããã«ãããªãã³
ããããã³K30ãã®20ïŒ ïŒ·ïŒïŒ¶æº¶æ¶²1.75ãšæ··
åãã湿最å¡ãæ¯åé ç²æ©äžã®750ÎŒïœã¹ã¯ãª
ãŒã³ã«éãããç²ã也ç¥ããåã³750ÎŒïœãµã
ãã«éããã åã«ã«ããã«934PãããªãŠã å¡©100mgããã³
ã«ã«ããããœãã³ãããªãŠã 20mgãå«æããã
ããã®ç²åã®1.26ïœåäœãã©ãããŒããµãã·ãš
ã«å ãŠãããããµãã·ãšã®å 容ç©ã¯æäžåã«æ°Ž
ïŒå¥œãŸããã¯20ã100mlïŒãšæ··åãããã æ¬çºæã®çµæç©ã®è¬å€ç¹æ§ã¯ïŒã€ã®in vivo
ã©ããã¢ãã«ã§è©äŸ¡ããã æ朰çãŸãã¯ç²èä¿è·æ§ããããŒãä»
ïŒRobert A.ïŒNezamis J.E.ïŒLancasster C.
and Hancher A.J.ïŒïŒGastroenterologyïŒ77ã
433ãïŒ1979ïŒã«ãããšã¿ããŒã«èªçºèå£æ»è©Šéš
ã§æž¬å®ããã ãã®è©Šéšæ³ã«ãããŠãéã¹ãã©ãŒã°ããŒã¬ã€
ïŒSpraueâDawleyïŒã©ããïŒ150ã170ïœïŒã
ïŒå¹ãã€å ¥ããåŠçœ®å18æé絶é£ãããïŒæé
æ°Žã奪ã€ããè¬å€ãŸãã¯è¬å€ããã¯ã«ãïŒmlïŒ
Kgã®çšééã§çµå£çã«æäžããïŒæ¯çŸ€ïœïŒ10ïŒïŒ
30ååŸã©ããã«80ïŒ ãšã¿ããŒã«ãçµå£æçšãã
ãïŒçšééïŒmlïŒKgïŒãïŒæéåŸã©ãããé éš
æµ®ãã€ã¹ãã±ãŒã·ãšã³ïŒcerrical dislocationïŒ
ã«ãã殺ãããçŽã¡ã«è ¹éšãéãèãé²åºãã
ãã èãé£éã®åºéšã§çµçŽ®ãã次ãã§åäºæ¯è žïŒ
ãïŒcmãšãšãã«åãåºãããèå 容ç©ãæ°Žã§ïŒ
åæŽæµãã次ãã§èã70ïŒ ïŒå·¥æ¥å€æ§ã¢ã«ã³ãŒ
ã«ïŒãçšããŠèšåŒµããè©Šéšåã«70ïŒ IMSäžã«ä¿
åãããèã倧匯沿ãã«éããæäžåŠçãç¥ã
ãªã芳å¯è ã«ããç²èãè©Šéšããããç å€ãèŠ
åçãªæ¹æ³ã§ããªã¡ãŒãã«ã§æž¬å®ããé·ããèš
é²ããèåœãã®å šç å€é·ã決å®ããããã¹ãŠã®
èãè©ŠéšããåŸã³ãŒãã解ããç å€æå·ã®ã²ã©
ããã©ããã®çŸ€åœãå¹³åç å€é·ïŒÂ±SEMïŒãš
ããŠè¡šããããããŒã¿ã®çµ±èšåæã¯ç¡å¯ŸããŒã¿
ã«å¯Ÿããã¹ããŠãŒãã³ããïœãè©ŠéšãçšããŠè¡
ãªã€ããååŠçå¹æã¯ïœå€ã0.05æªæºã§ããã°
ææãšæãããã察象ã®ããã¯ã«åŠç矀平åã
è¬å€åŠç矀ãšæ¯èŒãããšã¿ããŒã«ã«ããçãã
ç å€æœ°çããã®ä¿è·çã決å®ããã è¡šïŒã¯ã«ã«ããããœãã³ïŒãããªãŠã å¡©ïŒãŸ
ãã¯ã«ã«ããã«934PïŒãããªãŠã å¡©ïŒå«æãã
PH8.0ãæããçµæç©ã§åŸãããè©ŠéšããŒã¿ã
瀺ããè¡šïŒã¯æåã®å€åéãå«æããPH8.0ã®
çµæç©ã«å¯ŸããããŒã¿ã瀺ãã
ãè¡šã
ãè¡šã
è¡šïŒããããšã¿ããŒã«èªçºèå£æ»ã«å¯Ÿããæ
æãªä¿è·ã®ããã®æå°çšéãã«ã«ããããœãã³
1.2ïŒ ïŒä¿è·69.1ïŒ ïœïŒ0.01ïŒããã³ã«ã«ããã«
934P1ïŒ ïŒä¿è·39.1ïŒ ïœïŒ0.02ïŒã§ãã€ãã
ãšãç¥ããšãšãã§ãããã«ã«ããããœãã³ãšç°
ãªããã«ã«ããã«ã¯ãšã¿ããŒã«ã«ã®åœ±é¿ã«å¯Ÿã
40ïŒ ãã倧ããä¿è·ãéæããªãã€ãã è¡šïŒãããã«ã«ããã«934Pã®äžæŽ»æ§çšé
ïŒ0.42ïŒ ïŒãã«ã«ããããœãã³ã®äžæŽ»æ§çšé
ïŒ0.2ïŒ ïŒãšçµåãããšãã«ææãªä¿è·ïŒ66.6
ïŒ ãïœïŒ0.01ïŒãçãããããªãã¡çžä¹äœçšã
è¡šãããããšãç¥ãããšãã§ããã çµæç©ã®ã©ããã®èç²èã«å¯ŸãçµåïŒä»çïŒ
ããèœåã¯ã°ãªãŒã³ä»ïŒGreen A.P.ïŒLander
J.E. and Turner D.H.ïŒïŒJ.Pharm.
Pharmacol.ïŒ33ã348ãïŒ1981ïŒã®æ¹æ³ãåºã«
ããæ¹æ³ã«ãã枬å®ããããã®æ¹æ³ã¯èç²æ¶²äž
ã«ååšããé žæ§ã ã³å€ç³é¡ã«çµåããã«ããªã³
ææãã¢ã«ã·ã¢ã³ãã«ãŒïŒalcian blueïŒããçš
ãããçäœå ã§ããã®ææã¯å€ç³ãäŸãã°ïŒ«â
ã«ã©ã®âãã³ãã¢ã«ã®ããŒããã«ã«ããã·ã«ã
ãŒã¹ããã³ããµã³ã¿ã³ã䞊ã³ã«ããªã¢ã¯ãªã©ãŒ
ããäŸãã°ã«ã«ãã¡ã«ãšã®éœæ§åå¿ãäžããã è©Šéšæ³ã«ãããŠãéã¹ãã©ãŒã°âããŒã¬ã€ã©
ããïŒ130ã150ïœïŒãïŒå¹ãã€å ¥ããåŠçå18
æéå€éã絶é£ãããåŠçïŒïŒmlïŒKgã®çšéé
ã§çµå£æäžïŒåŸã©ããïŒæ¯çŸ€ïœïŒ10ïŒãé éšã
ã€ã¹ãã±ãŒã·ãšã³ã«ãã殺ãåããã«60åéã
ã®ãŸãŸã«ãããçŽã¡ã«è ¹éšãéããèãåãé¢
ããé£çµããçµæãé€ãã倧匯沿ãã«éããã
èã軜æµæ°Žäžã«ç©ããã«æŽæµããæ°·å·0.25Mã¹
ã¯ããŒã¹æº¶æ¶²10mläžã«çœ®ãããã¹ã¯ããŒã¹æº¶æ¶²
äžã®èã次ãã§ãšã¬ã¯ããããã¯ã¹ãã©ã³ã¹
ïŒSartorius1212MPïŒäžã§ç§€éããåèã®è¿äŒŒ
湿最ééã枬å®ãããèãã¹ã¯ããŒã¹æº¶æ¶²ãã
åãåºãããã³ã»ããã§è»œãæ¯ãéå°ã®ã¹ã¯ã
ãŒã¹ãé€ãããæŽæµããèã次ãã§æ°ã«èª¿è£œ
ããHClã§PH5.8ã«èª¿æŽãã0.05Mé ¢é žãããªãŠ
ã ã§ç·©è¡ãã0.15Mã¹ã¯ããŒã¹äžã®ã¢ã«ã·ã¢ã³
ãã«ãŒ8GXïŒã¢ã«ããªãããã±ãã«ã«ïŒææ溶
液ïŒïŒmgïŒmlïŒ10mläžã§æã æ¯ãåãããŠå®€æž©
ã§ïŒæéã€ã³ããŠãã€ããããèïŒããŸã¯é
è²ïŒã0.25Mã¹ã¯ããŒã¹æº¶æ¶²10mlïŒ2XïŒã§10
åéæŽæµãããã³ã»ããã§è»œãæ¯ãåãããŠé
å°ã®ã¹ã¯ããŒã¹ãé€å»ãã0.5Må¡©åãã°ãã·
ãŠã 溶液15mläžãæã åãããŠå®€æž©ã§ããã«ïŒ
æé眮ããåãåºããéè²ã®å¡©åãã°ãã·ãŠã
溶液ããžãšãã«ãšãŒãã«ãïŒmlïŒ2XïŒãšãšã
ã«ã30ç§éæ¯ãåããããæ°Žå±€ã®å åŠæ¿åºŠã䜿
ãæšãŠã»ã«ïŒïŒml容éãïŒcmå è·¯ïŒãçšãã»ã·
ã«ïŒCecilïŒ595ããŠã¢ã«ããŒã åå å 床èšäžã§
605nmã§æž¬å®ãããå šè³æãæ¯èŒããããã«çš
ãããã©ã³ã¯ïŒåç §ã»ã«ïŒã¯é žåãã°ãã·ãŠã
溶液ã§ãã€ããçµæã¯çµç¹ééïœåœãã®å åŠæ¿
床åäœã§ç€ºããããããŒã¿ã®çµ±èšåæã¯ç¡å¯Ÿã
ãŒã¿ã«å¯Ÿããã¹ããŠãŒãã³ããïœãè©Šéšãçšã
ãŠè¡ãªã€ããååŠçå¹æã¯ïœå€ã0.05æªæºã§ã
ãã°ææãšæããããå¯Ÿç §ããã³è©ŠéšçŸ€éã®çŸ
åçå·®ããŸã決å®ããã è¡šïŒã¯æè¬åŸ60åã§æž¬å®ããçš®ã ã®æ¿åºŠã®ã«
ã«ããã«934PïŒãããªãŠã å¡©ïŒãå«æããPH8.0
ãæããçµæç©ã§åŸãããè©ŠéšããŒã¿ã瀺ãã
è¡šïŒã¯ïŒæéã«ãããæéã«æž¬å®ããïŒïŒ ã«ã«
ããã«934PïŒãããªãŠã å¡©ïŒãå«æãPH8.0ãæ
ããçµæç©ã«å¯Ÿããçµæã瀺ãã
æãªä¿è·ã®ããã®æå°çšéãã«ã«ããããœãã³
1.2ïŒ ïŒä¿è·69.1ïŒ ïœïŒ0.01ïŒããã³ã«ã«ããã«
934P1ïŒ ïŒä¿è·39.1ïŒ ïœïŒ0.02ïŒã§ãã€ãã
ãšãç¥ããšãšãã§ãããã«ã«ããããœãã³ãšç°
ãªããã«ã«ããã«ã¯ãšã¿ããŒã«ã«ã®åœ±é¿ã«å¯Ÿã
40ïŒ ãã倧ããä¿è·ãéæããªãã€ãã è¡šïŒãããã«ã«ããã«934Pã®äžæŽ»æ§çšé
ïŒ0.42ïŒ ïŒãã«ã«ããããœãã³ã®äžæŽ»æ§çšé
ïŒ0.2ïŒ ïŒãšçµåãããšãã«ææãªä¿è·ïŒ66.6
ïŒ ãïœïŒ0.01ïŒãçãããããªãã¡çžä¹äœçšã
è¡šãããããšãç¥ãããšãã§ããã çµæç©ã®ã©ããã®èç²èã«å¯ŸãçµåïŒä»çïŒ
ããèœåã¯ã°ãªãŒã³ä»ïŒGreen A.P.ïŒLander
J.E. and Turner D.H.ïŒïŒJ.Pharm.
Pharmacol.ïŒ33ã348ãïŒ1981ïŒã®æ¹æ³ãåºã«
ããæ¹æ³ã«ãã枬å®ããããã®æ¹æ³ã¯èç²æ¶²äž
ã«ååšããé žæ§ã ã³å€ç³é¡ã«çµåããã«ããªã³
ææãã¢ã«ã·ã¢ã³ãã«ãŒïŒalcian blueïŒããçš
ãããçäœå ã§ããã®ææã¯å€ç³ãäŸãã°ïŒ«â
ã«ã©ã®âãã³ãã¢ã«ã®ããŒããã«ã«ããã·ã«ã
ãŒã¹ããã³ããµã³ã¿ã³ã䞊ã³ã«ããªã¢ã¯ãªã©ãŒ
ããäŸãã°ã«ã«ãã¡ã«ãšã®éœæ§åå¿ãäžããã è©Šéšæ³ã«ãããŠãéã¹ãã©ãŒã°âããŒã¬ã€ã©
ããïŒ130ã150ïœïŒãïŒå¹ãã€å ¥ããåŠçå18
æéå€éã絶é£ãããåŠçïŒïŒmlïŒKgã®çšéé
ã§çµå£æäžïŒåŸã©ããïŒæ¯çŸ€ïœïŒ10ïŒãé éšã
ã€ã¹ãã±ãŒã·ãšã³ã«ãã殺ãåããã«60åéã
ã®ãŸãŸã«ãããçŽã¡ã«è ¹éšãéããèãåãé¢
ããé£çµããçµæãé€ãã倧匯沿ãã«éããã
èã軜æµæ°Žäžã«ç©ããã«æŽæµããæ°·å·0.25Mã¹
ã¯ããŒã¹æº¶æ¶²10mläžã«çœ®ãããã¹ã¯ããŒã¹æº¶æ¶²
äžã®èã次ãã§ãšã¬ã¯ããããã¯ã¹ãã©ã³ã¹
ïŒSartorius1212MPïŒäžã§ç§€éããåèã®è¿äŒŒ
湿最ééã枬å®ãããèãã¹ã¯ããŒã¹æº¶æ¶²ãã
åãåºãããã³ã»ããã§è»œãæ¯ãéå°ã®ã¹ã¯ã
ãŒã¹ãé€ãããæŽæµããèã次ãã§æ°ã«èª¿è£œ
ããHClã§PH5.8ã«èª¿æŽãã0.05Mé ¢é žãããªãŠ
ã ã§ç·©è¡ãã0.15Mã¹ã¯ããŒã¹äžã®ã¢ã«ã·ã¢ã³
ãã«ãŒ8GXïŒã¢ã«ããªãããã±ãã«ã«ïŒææ溶
液ïŒïŒmgïŒmlïŒ10mläžã§æã æ¯ãåãããŠå®€æž©
ã§ïŒæéã€ã³ããŠãã€ããããèïŒããŸã¯é
è²ïŒã0.25Mã¹ã¯ããŒã¹æº¶æ¶²10mlïŒ2XïŒã§10
åéæŽæµãããã³ã»ããã§è»œãæ¯ãåãããŠé
å°ã®ã¹ã¯ããŒã¹ãé€å»ãã0.5Må¡©åãã°ãã·
ãŠã 溶液15mläžãæã åãããŠå®€æž©ã§ããã«ïŒ
æé眮ããåãåºããéè²ã®å¡©åãã°ãã·ãŠã
溶液ããžãšãã«ãšãŒãã«ãïŒmlïŒ2XïŒãšãšã
ã«ã30ç§éæ¯ãåããããæ°Žå±€ã®å åŠæ¿åºŠã䜿
ãæšãŠã»ã«ïŒïŒml容éãïŒcmå è·¯ïŒãçšãã»ã·
ã«ïŒCecilïŒ595ããŠã¢ã«ããŒã åå å 床èšäžã§
605nmã§æž¬å®ãããå šè³æãæ¯èŒããããã«çš
ãããã©ã³ã¯ïŒåç §ã»ã«ïŒã¯é žåãã°ãã·ãŠã
溶液ã§ãã€ããçµæã¯çµç¹ééïœåœãã®å åŠæ¿
床åäœã§ç€ºããããããŒã¿ã®çµ±èšåæã¯ç¡å¯Ÿã
ãŒã¿ã«å¯Ÿããã¹ããŠãŒãã³ããïœãè©Šéšãçšã
ãŠè¡ãªã€ããååŠçå¹æã¯ïœå€ã0.05æªæºã§ã
ãã°ææãšæããããå¯Ÿç §ããã³è©ŠéšçŸ€éã®çŸ
åçå·®ããŸã決å®ããã è¡šïŒã¯æè¬åŸ60åã§æž¬å®ããçš®ã ã®æ¿åºŠã®ã«
ã«ããã«934PïŒãããªãŠã å¡©ïŒãå«æããPH8.0
ãæããçµæç©ã§åŸãããè©ŠéšããŒã¿ã瀺ãã
è¡šïŒã¯ïŒæéã«ãããæéã«æž¬å®ããïŒïŒ ã«ã«
ããã«934PïŒãããªãŠã å¡©ïŒãå«æãPH8.0ãæ
ããçµæç©ã«å¯Ÿããçµæã瀺ãã
ãè¡šã
ãè¡šã
è¡šïŒããã«ã«ããã«934PïŒãããªãŠã å¡©ïŒã
çšéé¢é£ç¶æ ã§ã©ããèç²èã«å®¹æã«çµåãã
ããšãç¥ãããšãã§ãããè¡šïŒããçµåãïŒæ
éãŸã§æç¶ããããšãç¥ãããšãã§ããã ããã«ãïŒã€ã®in vivoã©ããã¢ãã«ãçšã
ãŠã«ã«ããã«934Pãä»ã®é žæ§éåäœã§ä»£çœ®ã
ãç 究ãè¡ãªã€ããè¡šïŒã¯ïŒè©Šéšã«PH8.0ãæ
ããé žæ§éåäœïŒãããªãŠã å¡©ïŒã®ã¿ãæãã
çµæç©ã«å¯Ÿããè©ŠéšããŒã¿ã瀺ããè¡šïŒã¯ã«ã«
ããããœãã³ïŒãããªãŠã å¡©0.2ïŒ ïŒãšã®çµå
ãã«ã€ããŠã®ãšã¿ããŒã«èªçºå£æ»è©Šéšã«ããã
ããŒã¿ã瀺ãã
çšéé¢é£ç¶æ ã§ã©ããèç²èã«å®¹æã«çµåãã
ããšãç¥ãããšãã§ãããè¡šïŒããçµåãïŒæ
éãŸã§æç¶ããããšãç¥ãããšãã§ããã ããã«ãïŒã€ã®in vivoã©ããã¢ãã«ãçšã
ãŠã«ã«ããã«934Pãä»ã®é žæ§éåäœã§ä»£çœ®ã
ãç 究ãè¡ãªã€ããè¡šïŒã¯ïŒè©Šéšã«PH8.0ãæ
ããé žæ§éåäœïŒãããªãŠã å¡©ïŒã®ã¿ãæãã
çµæç©ã«å¯Ÿããè©ŠéšããŒã¿ã瀺ããè¡šïŒã¯ã«ã«
ããããœãã³ïŒãããªãŠã å¡©0.2ïŒ ïŒãšã®çµå
ãã«ã€ããŠã®ãšã¿ããŒã«èªçºå£æ»è©Šéšã«ããã
ããŒã¿ã瀺ãã
ãè¡šã
ãè¡šã
è¡šïŒãããããªãŠã ã«ã«ããã·ã¡ãã«ã»ã«ã
ãŒã¹ããã³ïœâã«ã©ã®ãŒãã³ïŒç¡«é žåå€ç³ïŒã
ãšãã«ãã«ã«ããã«934Pã§èªããããã®ã«é¡
䌌ããçšåºŠã®ã©ãããšã¿ããŒã«å£æ»è©Šéšã«ãã
ãä¿è·ãçããããã©ããäž¡ããªããŒã¯in
vivoã§ã©ããèç²èã«å¯Ÿããææãªçµå芪åå
ã瀺ããªãã€ãããšãç¥ãããšãã§ãããã¢ã«
ã®ã³é žãããªãŠã ããã³ããµã³ã¿ã³ã¬ã ã¯ã©ã®
è©Šéšã«ã¯ææãªçµæãçããªãã€ããè¡šïŒã¯è©Š
éšããéåäœäžã«ã«ããã«934Pã®ã¿ãã«ã«ã
ãããœãã³ãšçµåããšãã«ã©ãããšã¿ããŒã«å£
æ»è©Šéšã«ãããŠçžä¹äœçšã瀺ããããšã瀺ãã è¡šïŒã¯æè¬60ååŸã«æž¬å®ããçš®ã ã®ããªã¢ã¯
ãªã©ãŒãã®ãããªãŠã å¡©ã®0.5ïŒ ãå«æããçµ
æç©ã«ããçµåç 究ã§åŸãããè©ŠéšããŒã¿ã瀺
ãã
ãŒã¹ããã³ïœâã«ã©ã®ãŒãã³ïŒç¡«é žåå€ç³ïŒã
ãšãã«ãã«ã«ããã«934Pã§èªããããã®ã«é¡
䌌ããçšåºŠã®ã©ãããšã¿ããŒã«å£æ»è©Šéšã«ãã
ãä¿è·ãçããããã©ããäž¡ããªããŒã¯in
vivoã§ã©ããèç²èã«å¯Ÿããææãªçµå芪åå
ã瀺ããªãã€ãããšãç¥ãããšãã§ãããã¢ã«
ã®ã³é žãããªãŠã ããã³ããµã³ã¿ã³ã¬ã ã¯ã©ã®
è©Šéšã«ã¯ææãªçµæãçããªãã€ããè¡šïŒã¯è©Š
éšããéåäœäžã«ã«ããã«934Pã®ã¿ãã«ã«ã
ãããœãã³ãšçµåããšãã«ã©ãããšã¿ããŒã«å£
æ»è©Šéšã«ãããŠçžä¹äœçšã瀺ããããšã瀺ãã è¡šïŒã¯æè¬60ååŸã«æž¬å®ããçš®ã ã®ããªã¢ã¯
ãªã©ãŒãã®ãããªãŠã å¡©ã®0.5ïŒ ãå«æããçµ
æç©ã«ããçµåç 究ã§åŸãããè©ŠéšããŒã¿ã瀺
ãã
ãè¡šã
ãè¡šã
ç·ç¶
ã¢ãã³ãã¹ 8.2 41.2 ïŒ0.001
ã«ã«ããã«907 8.5 37.6 ïŒ0.001
è¡šïŒããè©Šéšãããã¹ãŠã®ããªã¢ã¯ãªã©ãŒã
ã®ãããªãŠã å¡©ã§çµåã®å¢å ããã€ãããšãç¥
ãããšãã§ããã è¡šïŒã¯ã©ãããšã¿ããŒã«å£ç¥è©Šéšã«ãããŠå®
æœäŸåŸãããè©ŠéšããŒã¿ã瀺ããã
ã¢ãã³ãã¹ 8.2 41.2 ïŒ0.001
ã«ã«ããã«907 8.5 37.6 ïŒ0.001
è¡šïŒããè©Šéšãããã¹ãŠã®ããªã¢ã¯ãªã©ãŒã
ã®ãããªãŠã å¡©ã§çµåã®å¢å ããã€ãããšãç¥
ãããšãã§ããã è¡šïŒã¯ã©ãããšã¿ããŒã«å£ç¥è©Šéšã«ãããŠå®
æœäŸåŸãããè©ŠéšããŒã¿ã瀺ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ã«ã«ããããœãã³ãããªãŠã ãšããªã¢ã¯ãª
ã«é žãããªãŠã ãšãïŒïŒ20ãïŒïŒïŒã®ééæ¯ã§
å«ããèçãŸãã¯èâåäºæ¯è žæœ°çã®æ²»çã«äœ¿
çšããããã®ææ¶åæ§æœ°ççµæç©ã ïŒ ã«ã«ããããœãã³ãããªãŠã ãšããªã¢ã¯ãª
ã«é žãããªãŠã ãšãïŒïŒïŒãïŒïŒïŒã®ééæ¯ã§
å«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ææ¶åæ§æœ°
ççµæç©ã ïŒ ééæ¯ãïŒïŒïŒãïŒïŒïŒã§ãããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®ææ¶åæ§æœ°ççµæç©ã ïŒ ããªã¢ã¯ãªã«é žãããªãŠã ãã«ã«ãã¡ã«ã
ããªãŠã ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒ
é ã®ããããäžé ã«èšèŒã®ææ¶åæ§æœ°ççµæ
ç©ã ïŒ ã«ã«ãã¡ã«ãããªãŠã ãçŽ3000000ã®åå
éãæããããªã¢ã¯ãªã«é žãããªãŠã ã§ããã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ææ¶åæ§æœ°ççµæ
ç©ã ïŒ ã«ã«ããããœãã³ãããªãŠã ãšããªã¢ã¯ãª
ã«é žãããªãŠã ãšãïŒïŒ20ãïŒïŒïŒã®ééæ¯ã§
å«ã¿ãããã«å¶é žå€ãå«ããèçãŸãã¯èâå
äºæ¯è žæœ°çã®æ²»çã«äœ¿çšããããã®ææ¶åæ§æœ°
ççµæç©ã ïŒ å¶é žå€ãçé žæ°ŽçŽ ãããªãŠã ãçé žã«ã«ã·
ãŠã ãŸãã¯æ°Žé žåã¢ã«ãããŠã ããããã¯ãã
ãã®æ··åç©ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®ææ¶åæ§æœ°ççµæç©ã ïŒ ããã«ã¢ã«ã®ã³é žãããªãŠã ãçé žã«ã«ã·
ãŠã ããã³çé žæ°ŽçŽ ãããªãŠã ãšãšãã«å«ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ããããäžé
ã«èšèŒã®ææ¶åæ§æœ°ççµæç©ã ïŒ 7.5ã9.5ã®PHãæããæ°Žæ§çµæç©ã®åœ¢æ ã®
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ããããäžé
ã«èšèŒã®ææ¶åæ§æœ°ççµæç©ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838323624A GB8323624D0 (en) | 1983-09-02 | 1983-09-02 | Medicinal compositions |
| GB8323624 | 1983-09-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6072832A JPS6072832A (ja) | 1985-04-24 |
| JPH056527B2 true JPH056527B2 (ja) | 1993-01-26 |
Family
ID=10548263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59180224A Granted JPS6072832A (ja) | 1983-09-02 | 1984-08-29 | ææ¶åæ§æœ°ççµæç© |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4652446A (ja) |
| EP (1) | EP0136006B1 (ja) |
| JP (1) | JPS6072832A (ja) |
| AU (1) | AU560528B2 (ja) |
| CA (1) | CA1232203A (ja) |
| DE (1) | DE3483900D1 (ja) |
| DK (1) | DK162473C (ja) |
| GB (2) | GB8323624D0 (ja) |
| GR (1) | GR80238B (ja) |
| IE (1) | IE57474B1 (ja) |
| NZ (1) | NZ209080A (ja) |
| PT (1) | PT79167B (ja) |
| ZA (1) | ZA845988B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451411A (en) * | 1993-10-15 | 1995-09-19 | University Of Washington | Methods and compositions for the oral delivery of therapeutic agents |
| IN186245B (ja) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| CH697081A5 (de) * | 2002-01-22 | 2008-04-30 | Andreas F Dr Schaub | Zusammensetzung fÌr die UnterstÌtzung der Geburt eines menschlichen Föten. |
| DE102004054552A1 (de) * | 2004-11-11 | 2006-05-18 | Hcb Happy Child Birth Holding Ag | Neue Zusammensetzung zur Erleichterung der Humangeburt |
| US7795311B2 (en) | 2007-10-15 | 2010-09-14 | Pittsburg State University | Methods and compositions for the management of soil-borne fungal diseases |
| MX347598B (es) * | 2010-07-20 | 2017-05-03 | C-Ip S A * | Suspension de compuesto que contiene boro. |
| JP6641626B2 (ja) * | 2015-12-25 | 2020-02-05 | ãšã¹ãšã¹è£œè¬æ ªåŒäŒç€Ÿ | å¶é žçšå»è¬çµæç© |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2912358A (en) * | 1955-11-02 | 1959-11-10 | Bristol Myers Co | Antacid preparations containing acrylic acid polymers and magnesium antacids |
| US3957973A (en) * | 1972-01-14 | 1976-05-18 | Nippon Kayaku Kabushiki Kaisha | Composition and method for gastric ulcer-prevention and pica-prevention of swine |
| GB1524740A (en) * | 1976-11-09 | 1978-09-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions for use in the suppression of gastric reflux |
-
1983
- 1983-09-02 GB GB838323624A patent/GB8323624D0/en active Pending
-
1984
- 1984-07-27 EP EP84305124A patent/EP0136006B1/en not_active Expired - Lifetime
- 1984-07-27 DE DE8484305124T patent/DE3483900D1/de not_active Expired - Lifetime
- 1984-07-27 GB GB08419243A patent/GB2145626B/en not_active Expired
- 1984-07-31 US US06/636,229 patent/US4652446A/en not_active Expired - Fee Related
- 1984-08-01 NZ NZ209080A patent/NZ209080A/en unknown
- 1984-08-02 ZA ZA845988A patent/ZA845988B/xx unknown
- 1984-08-03 CA CA000460323A patent/CA1232203A/en not_active Expired
- 1984-08-13 IE IE2085/84A patent/IE57474B1/en not_active IP Right Cessation
- 1984-08-29 JP JP59180224A patent/JPS6072832A/ja active Granted
- 1984-08-29 GR GR80238A patent/GR80238B/el unknown
- 1984-08-31 PT PT79167A patent/PT79167B/pt not_active IP Right Cessation
- 1984-08-31 AU AU32605/84A patent/AU560528B2/en not_active Ceased
- 1984-08-31 DK DK417784A patent/DK162473C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GB8323624D0 (en) | 1983-10-05 |
| DE3483900D1 (de) | 1991-02-14 |
| GB8419243D0 (en) | 1984-08-30 |
| NZ209080A (en) | 1988-01-08 |
| EP0136006B1 (en) | 1991-01-09 |
| EP0136006A3 (en) | 1988-07-27 |
| PT79167A (en) | 1984-09-01 |
| CA1232203A (en) | 1988-02-02 |
| IE842085L (en) | 1985-03-02 |
| DK417784A (da) | 1985-03-03 |
| AU3260584A (en) | 1985-03-07 |
| GR80238B (en) | 1985-01-02 |
| DK417784D0 (da) | 1984-08-31 |
| GB2145626B (en) | 1986-07-30 |
| DK162473B (da) | 1991-11-04 |
| IE57474B1 (en) | 1993-01-27 |
| JPS6072832A (ja) | 1985-04-24 |
| DK162473C (da) | 1992-04-06 |
| US4652446A (en) | 1987-03-24 |
| PT79167B (en) | 1986-08-19 |
| ZA845988B (en) | 1985-04-24 |
| GB2145626A (en) | 1985-04-03 |
| EP0136006A2 (en) | 1985-04-03 |
| AU560528B2 (en) | 1987-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU773549B2 (en) | Soft chewable tablets | |
| CN1230153C (zh) | å ·æå¢åŒºåŽ©è§£æ§çèèå è¡£çç»åç© | |
| US5213794A (en) | Antacid preparation having a prolonged gastric residence time | |
| RU2301662C2 (ru) | ЀаÑЌаÑевÑОÑеÑкОй пÑепаÑаÑ, ÑПЎеÑжаÑОй ОМгОбОÑÐŸÑ Ð¿ÑПÑПММПй Ð¿ÐŸÐŒÐ¿Ñ Ðž аМÑаÑÐžÐŽÑ | |
| EP0193400B1 (en) | Pharmaceutical compositions | |
| JP2635407B2 (ja) | å»è¬åãããé çµæç© | |
| JPH08503482A (ja) | éšåæ°ŽçŽ æ·»å æ€ç©æ²¹ã§è¢«èŠãããã·ã¡ããžã³é¡ç²å€ | |
| GB2243549A (en) | Medicament containing triclosan for treating gastrointestinal disorders | |
| PL199445B1 (pl) | Zastosowanie kompozycji soli kwasu alginowego i kompozycja soli kwasu alginowego | |
| US5648092A (en) | Sucralfate chewable tablet | |
| KR100976071B1 (ko) | ì¡°ì±ë¬Œ ëŽììì ëë ì¡°ì±ë¬Œì êŽë šë ê°ì ì± | |
| JPH056527B2 (ja) | ||
| DK154265B (da) | Fremgangsmaade til stabilisering af en vandig mavesyreneutraliserende suspension | |
| EP2269589B1 (en) | Ion binding polymers and uses thereof | |
| Brooks Jr | Sucralfate: Nonulcer uses. | |
| JPS6143118A (ja) | å»è¬çµæç© | |
| EP0715520B1 (en) | Use of a suspension based on sucralphate gel as antacid | |
| EP0974361A1 (en) | Method of using antacid agent and pharmaceutical preparation containing antacid agent | |
| WO2022118107A1 (en) | Multi-layered particle comprising simethicone | |
| CN116098863A (zh) | äžç§ç¡«ç³éå£ææ··æ¬æ¶²åå ¶å¶å€æ¹æ³ |